PCH
ALXO icon

Polar Capital Holdings’s ALX Oncology ALXO Stock Holding History

Polar Capital Holdings’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-32,500
Closed -$2.8M – 328
2020
Q4 		$2.8M Buy
+32,500
New +$1.96M 0.02% 273

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings's ALXO Position: Q1 2021 in Review

Polar Capital Holdings sold out of ALX Oncology (ALXO) in Q1 2021, closing a stake of 32,500 shares — an estimated $2.8M sold.

Polar Capital Holdings first reported a position in ALXO in Q4 2020 and held it in 1 quarter. The position peaked at $2.8M in Q4 2020. 93 funds tracked by Wall St. Rank hold ALXO as of Q1 2021.

  • Polar Capital Holdings reported no remaining ALX Oncology position as of Q1 2021 after selling out during the quarter.
  • Polar Capital Holdings sold 32,500 ALX Oncology shares in Q1 2021, an estimated $2.8M.
  • Polar Capital Holdings first reported a position in ALX Oncology in Q4 2020 and held it in 1 quarter.
  • Polar Capital Holdings's ALX Oncology position peaked at $2.8M in Q4 2020.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2021.

Based on Polar Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.